ANTHOS THERAPEUTICS
Accelerating the development of life-preserving therapies for patients at high-risk of cardiovascular diseases

Alex Yi, MD PhD, is a Senior Director Medical Affairs at Anthos Therapeutics.

Dr. Yi has more than 5 years of industry experience in early and late phase clinical development programs in the cardiovascular, metabolic, and rare disease therapeutic areas. Dr. Yi previously served as a Director of Clinical Development at Vertex Pharmaceuticals and Director in Translational Medicine at the Novartis Institutes for BioMedical Research.

Dr. Yi received an MD and PhD in Neuroscience at the University of California, San Francisco. He completed his training in Internal Medicine at NY Presbyterian Hospital/Weill Cornell Medical College and fellowship in cardiovascular diseases at Massachusetts General Hospital.

Dan is the Chief Medical Officer at Anthos Therapeutics. Dan has more than 16 years in drug development, initially at Merck and most recently at Cardurion Pharmaceuticals. Dan joined Cardurion in May 2017 as its first CEO after a diverse 14 year career at Merck & Co. (NYSE: MRK), that included leadership roles in early and late clinical development and cardiovascular discovery. He was actively involved in business development, acquisitions, and numerous licensing opportunities and spent a year as Chief of Staff for Merck’s CEO, Ken Frazier. Dan’s career at Merck culminated as SVP and Therapeutic Area Head for Cardiovascular, Diabetes, Endocrine, and Women’s Health Programs and he was responsible for the central coordination and strategic oversight of Merck’s R&D organization in China across all therapeutic areas.

In addition to his executive duties, Dr. Bloomfield was a founding member and co-chair of the Cardiac Safety Research Consortium (a public private partnership with the FDA, academia and industry) and served as Rapporteur for the ICH E14 implementation working group for 9 years.

After finishing a BA in Chemistry at Haverford College, Dan took a Master's degree in Social Anthropology at Oxford University as a Rhodes Scholar. Upon his return to the US, he attended Harvard Medical School and subsequently did his Internal Medicine and Cardiology training at Columbia before joining the faculty. As an Associate Professor his academic research was supported by grants from the NIH (K08, R01, K24), multiple foundations, and industry.

Debra Freedholm is Head of Clinical Operations at Anthos Therapeutics.

Ms. Freedholm is a clinical and business operations executive with more than 25 years’ experience in the pharmaceutical industry in a variety of leadership roles across Clinical Research, Clinical Operations, Business Operations and Corporate Licensing at Bristol-Myers Squibb (NYSE: BMS) and Merck (NYSE: MRK).

Ms. Freedholm has extensive experience in building new organizations in diverse areas across pharma, academic institutions and private industry. Most recently, Ms. Freedholm was Vice President, Clinical Trial Solutions at Axiom Law.

Prior to joining the pharmaceutical industry, Ms. Freedholm spent 10 years as an ICU Nurse, Research Study Coordinator and Head Nurse of a Clinical Research Center. Ms. Freedholm has a Bachelor of Arts Degree in Nursing from Gustavus Adolphus College and an MBA from The Wharton School, University of Pennsylvania and has authored several peer-reviewed scientific papers and a text book chapter in the field of endocrinology and drug safety.

Janeen Salter is the Director of Clinical Operations. Janeen is an RN with over 18 years of study management and performance management experience, most recently, as a Clinical Science Expert for NIBR. During her tenure at NIBR and Novartis Pharma, she managed small and large molecule development across phases I-III in multiple therapeutic areas and established and managed KPIs and performance for the development organization. Importantly, Janeen has in-depth knowledge of MAA868 and was the Study Lead on the MAA868 early development studies conducted by Novartis. Janeen lives in Doylestown, PA and can be reached at 215-407-7883.

Bio coming soon.

John Glasspool is CEO and member of the Board of Directors of Anthos Therapeutics.

Mr. Glasspool is also a member of the Board of Directors of Dalcor Corporation. He was formerly the Executive Vice President, Head of Corporate Strategy and Customer Operations at Baxalta Incorporated (NYSE: BXLT), formerly Baxter BioScience (NYSE: BAX).

Prior to joining Baxter in August 2012, Mr. Glasspool was Head of Region Europe and Novartis Vaccines & Diagnostics (NYSE: NVS), a member of the V&D Executive Committee. Mr. Glasspool served as a board member, Vice President and President of the European Vaccine manufacturers (EVM), from 2010 until December 2012.

Previously, Mr. Glasspool was Head of Global Pricing & Market Access and Head of Global Commercial Operations in Novartis Pharma, where he led the functions in embedding the needs of customers and consumers for brands at all stages of their lifecycle development, launch, and in market. Mr. Glasspool joined Novartis as Head of Marketing for Neuroscience. He was promoted to Global Head Cardiovascular & Metabolism Business Franchise in 2006, during which time he grew the franchise sales over a three-year period.

Jonathan Freeman, Ph.D. is the Co-Founder and Chief Operating Officer at Anthos Therapeutics.

Dr. Freeman is a Blackstone Life Sciences Senior Advisor and has over 20 years of practical industry experience within the healthcare private equity, start-up, business development, corporate development, and M&A sectors. Dr. Freeman previously served as Senior Vice President of Strategy / Portfolio Management, and Head of Business Development and Licensing at Merck KgaA (FWB: MRK); CBO, Vedanta Biosciences (LSE: PRTC); Head of M&A and Licensing at Baxter International (NYSE: BAX); and Director of Corporate Development at Serono (NYSE: SRA).

Dr. Freeman received a Ph.D. in Molecular Pharmacology and Drug Metabolism from the ICRF (now CRUK), an MBA jointly from the Universities of Versailles, Paris-Saclay, and Webster, St Louis, and both an MA and First-Class BA (Hons) from Cambridge University. Jonathan was previously Vice President of the Swiss PLG, an EMBO fellow at the Swiss Institute of Experimental Cancer Research (ISREC) and has authored several peer-reviewed scientific papers in the fields of oncology and drug metabolism.

Ms. Mallett is a finance and business operations executive with over 20 years experience in finance leadership roles in the life sciences industry and over 25 years of collective experience in finance and accounting.

Prior to joining Anthos Therapeutics, Ms. Mallett served as Consulting VP Finance for multiple biotech startup’s in the Boston area, including Beam Therapeutics & Neurobo Pharmaceuticals, playing a key role in supporting their build and establishing financial & operational capability needed to support the build and subsequent growth. Prior to that, Ms. Mallett served as CFO at Hemanext; Head of Finance, R&D and Head of Finance, Biosimilars Commercial at Baxalta (the spinout of Baxter Healthcare’s Bioscience Division). Prior to that, Ms. Mallett spent many years at Pfizer where she held various finance leadership positions supporting the Clinical Development organization.

Ms. Mallett has a Bachelor of Arts Degree in Business and an MS in Management from Eastern Nazarene College.

Bio coming soon.

Bio coming soon.

Nicholas Galakatos, Ph.D. is Chairman of the Board of Directors of Anthos Therapeutics.

Dr. Galakatos is the Head of Blackstone Life Sciences, having joined Blackstone as part of its acquisition of Clarus in December of 2018. Prior to joining Blackstone, Dr. Galakatos was a co-Founder and Managing Director of Clarus since the firm's inception in 2005. Dr. Galakatos has over 30 years of industry and investment experience in the healthcare sector and has led investments in biotechnology, pharmaceutical company partnerships and diagnostics, from startups to commercial-stage companies. Prior to Clarus, Dr. Galakatos was a General Partner at MPM Capital, a healthcare venture capital firm.

Paris Panayiotopoulos is a member of the Board of Directors of Anthos Therapeutics.

Mr. Panayiotopoulos is a Managing Director in the Blackstone Life Sciences group, having joined Blackstone as part of its acquisition of Clarus in December of 2018. Mr. Panayiotopoulos is focused on growth investments in the biopharmaceutical space.

In over twenty years in the biopharmaceutical industry, Mr. Panayiotopoulos has served on the Board of Directors of a number of start-up to commercialization stage companies, as CEO and a member of the Board of Directors of ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA, sold to Takeda Pharmaceuticals in 2017), and as President of the US, Japan and Serono R&D Institute biopharmaceutical businesses of Merck KgaA (FWB: MRK).

Scott Beardsley is a member of the Board of Directors of Anthos Therapeutics.

Mr. Beardsley joined Novo Ventures (US) Inc. in San Francisco, California in 2012. Previously, he was a board member of Aerocrine AB.

From 2009-2012, Mr. Beardsley was part of Novo A/S’ Growth Equity team. Prior to joining Novo A/S he was a Managing Director at JP Morgan in San Francisco, heading the firm's West Coast biopharmaceuticals effort. Prior to that, Mr. Beardsley led Piper Jaffray's US biopharmaceuticals investment banking practice and was a member of the Health Care Group at Montgomery Securities. During his tenure as an investment banker, Mr. Beardsley originated and executed numerous transactions.

Mr. Beardsley holds an MBA from UCLA's Anderson Graduate School of Management and a BS from Colorado State University.

Ari Brettman, M.D. is a member of the Board of Directors of Anthos Therapeutics.

Dr. Brettman is a Principal at Blackstone Life Sciences, having joined Blackstone as part of its acquisition of Clarus in December of 2018. Dr. Brettman joined Clarus in September 2014.

Dr. Brettman is focused on investments across the firm's portfolio, including startups and partnerships with pharmaceutical companies. Prior to Clarus, Dr. Brettman completed a residency in internal medicine and a fellowship in cardiology at Massachusetts General Hospital. Dr. Brettman was also an NIH-sponsored post-doctoral fellow at the MGH Center for Systems Biology, where he studied the autophagy of lipid droplets and used electronic medical record-based big data analytics at Partners Healthcare to conduct clinical research and improve disease management. Dr. Brettman is a member of the Board of Directors of Praxis Precision Medicines, a startup in genetically defined neuropsychiatric disorders.

Dr. Shaun R. Coughlin, M.D, Ph.D. is an Observer to the Board of Directors of Anthos Therapeutics.

Dr. Coughlin has been Global Head of Cardiovascular & Metabolism at Novartis AG (NYSE: NVS) since August 2017.

Dr. Coughlin was appointed Professor of Medicine in 1996 and Professor of Molecular and Cellular Pharmacology in 1997 at the University of California, San Francisco ('UCSF'), where he served until 2017.

During his time at UCSF, Dr. Coughlin also served as the Director of the Cardiovascular Research Institute and the Director of Daiichi Research Center. Dr. Coughlin is also a Member of the editorial boards of Trends in Cardiovascular Medicine, Molecular Medicine and Journal of Clinical Investigation.

Dr. Richard C. Pasternak has spent the last 37 years as an academic and biopharmaceutical clinician-scientist. He is currently a Clinical Professor (Dept of Medicine) at the Weill Cornell Medical College, , and is a strategic consultant. He has served on multiple Boards and presently is on the Boards of Cerenis Therapeutics (now ABIONYX Pharma) (Board Chairman; Chair, compensation committee), where he also served as CEO 2018-19, Anthos Therapeutics (Clinical Committee), and Magenta Medical Ltd.(Chair, Compensation Committee).

Dr. Pasternak retired from Merck and Co. in 2010, where he had been Vice President, Clinical Research and Head Cardiovascular Therapeutic Area (2004-2008), and Vice President, Head of Global Scientific Affairs and Scientific Leadership (2008-2010). He served as a key senior executive in a communications role for Merck regarding critical issues related to worldwide scientific affairs. Dr. Pasternak worked on key strategic business development issues, regulatory affairs, medical affairs, and political affairs; and he was also a senior management policy liaison for medical and scientific issues.

Prior to joining Merck, Dr. Pasternak was Director of Preventive Cardiology and Cardiac Rehabilitation at the Massachusetts General Hospital, and an Associate Professor of Medicine at Harvard Medical School, having been on the Harvard faculty since 1983. He received his B.A. and M.D. from Yale University and completed his medical and cardiology training at the Massachusetts General Hospital.

Dr. Pasternak has had a long-standing research interest in vascular disease, lipid disorders and atherosclerosis, as well as in epidemiology, prevention, and patterns of practice and disease management. He was a member of the NIH's Coordinating Committee of the National Cholesterol Education Program (NCEP) and of the third Adult Treatment Panel (ATP III), has served on many national and international committees, and has published and spoken extensively.

Greg Norden is the former Chief Financial Officer of Wyeth and has been a member of our board since 2019. Mr Norden also serves on the Boards of Zoetis, the leading animal health company; Royalty Pharma, the industry leader in acquiring revenue-producing intellectual property; Univision, the leading multimedia company serving Hispanic America; NanoString, a provider of life science tools for translational research and molecular diagnostic products; and Entasis Therapeutics, a clinical stage biopharmaceutical company focused on the discovery and development of novel antibacterial products. Mr Norden is a former director of WelchAllyn, Lumara Health and Human Genome Sciences. In addition, Mr Norden is the Managing Director of G9 Capital Group, LLC, which invests in early stage ventures and provides corporate advisory and board services.